Sunday, June 1, 2025

Latest

Trulieve: Canaccord Retains $97 Price Target Following Harvest Health Transaction

On October 1, Trulieve Cannabis (CSE: TRUL) announced that they completed their $1.75 billion acquisition of Harvest Health (CSE: HARV). Harvest shareholders received 0.1170 shares of Trulieve for each subordinate voting share held. Trulieve issued a total of 50.9 million shares. The pro-forma second quarter revenue would have been $317.6 million.

A number of analysts raised their 12-month price targets off the back of the completed acquisition. This brought the average 12-month price target up to C$84.80, or a 137% upside. There are 17 analysts covering the stock, with 5 analysts having strong buy ratings and the other 12 have buy ratings. The street high sits at C$132 from Stifel-GMP while the lowest comes in at C$54.

In Canaccord’s note, they elected to just revise their estimates while keeping their Buy rating and C$97 price target the same. They say that beyond the attractive assets in Florida and Arizona, Pennsylvania is one of the key reasons why they like this transaction. They write, “Florida and Pennsylvania also offer potential significant adult-use upside beyond what we have included in our estimates.”

Canaccord also commends Trulieve on raising $350 million at 8% with no warrant, saying that this has been the most attractive term in the space. This, combined with the $55 million they got from selling Harvest’s Florida license, makes Trulieve’s balance sheet “well-positioned to fund organic growth in these key markets.” Canaccord believes that it will use its balance sheet to focus on its adult-use markets, specifically Arizona and Massachusetts as well as keeping its eyes out for acquisitions.

Below you can see Canaccord’s updated 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Alamos Gold Q1 Earnings: The Inside Scoop

Cerrado Gold Q4 Earnings: The Turnaround is Working

B2GOLD Q1 Earnings: Revenue Up, Production & Cash Flow Decline

Recommended

Canadian Copper: The $172M Combined Strategy PEA

ESGold Begins Concentration Tests Ahead Of First Production

Related News

Hexo Corp: Canaccord Cuts Target To $0.25 After Guidance Withdrawal

Earlier this week Hexo Corp (TSX: HEXO) reported its fiscal third-quarter ending April 30th. The...

Thursday, June 16, 2022, 04:32:00 PM

Alamos Gold: Canaccord Lifts Target To $13 On Phase 3+ Expansion Study Results

Alamos Gold Inc. (TSX: AGI) announced their phase 3+ expansion study of Island Gold located...

Saturday, July 2, 2022, 01:20:00 PM

Amazon Consensus Price Target Rises Following Strong Earnings

Amazon.com Inc (NASDAQ: AMZN) hit a new high on Friday, getting close to a $2...

Wednesday, May 5, 2021, 10:39:00 AM

Amazon: BMO Anticipates Revenue To Hit High End Of Guidance

Amazon.com Inc (NASDAQ: AMZN) announced that it will be reporting its third quarter results on...

Saturday, October 23, 2021, 12:53:00 PM

Alamos Gold: BMO Production Estimates For Q4 Comes In High

On January 17th, Alamos Gold Inc. (TSX: AGI) reported its fourth quarter and full-year production...

Sunday, February 6, 2022, 11:13:00 AM